Suven Pharma Q3 Results: Net profit surges 78% to Rs 83 crore, revenue up 40%

Suven Pharma, backed by Advent, reported a 78% year-on-year rise in net profit to Rs 83.3 crore for Q3FY25 driven by strong demand and business development efforts. Revenue grew 40% to Rs 307.2 crore, led by a surge in CDMO business. The company also advanced several molecules to Phase 3 trials and added a new strategic customer.

from Stocks-Markets-Economic Times https://ift.tt/R1WjFoD